Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody. - Wikidata - wikimedia - TriplyDB

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

http://www.wikidata.org/entity/Q33798442

about

Humanized PA14 (a monoclonal CCR5 antibody) for treatment of people with HIV infection Monoclonal CCR5 antibody for treatment of people with HIV infection CCR5 antagonism in HIV infection: current concepts and future opportunities Closing the door to human immunodeficiency virus.Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.Phase 2a study of the CCR5 monoclonal antibody PRO 140 administered intravenously to HIV-infected adults.Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases CCR5 antibodies HGS004 and HGS101 preferentially inhibit drug-bound CCR5 infection and restore drug sensitivity of Maraviroc-resistant HIV-1 in primary cells.Combinatorial anti-HIV gene therapy: using a multipronged approach to reach beyond HAART The isolation of novel phage display-derived human recombinant antibodies against CCR5, the major co-receptor of HIV The critical need for alternative antiretroviral formulations, and obstacles to their development.CCR5 blockade is well tolerated and induces changes in the tissue distribution of CCR5+ and CD25+ T cells in healthy, SIV-uninfected rhesus macaques Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.Gene Expression Profiling of Tuberculous Meningitis Co-infected with HIV Host Factors and HIV-1 Replication: Clinical Evidence and Potential Therapeutic Approaches A vaccine against CCR5 protects a subset of macaques upon intravaginal challenge with simian immunodeficiency virus SIVmac251.Recent advances in antiretroviral drugs.Immunotherapeutic restoration in HIV-infected individuals.Pharmacological modulation of chemokine receptor function.Candidate antibody-based therapeutics against HIV-1.Effect of HIV-1 subtype and tropism on treatment with chemokine coreceptor entry inhibitors; overview of viral entry inhibition.Protein/peptide-based entry/fusion inhibitors as anti-HIV therapies: challenges and future direction.Engineering broadly neutralizing antibodies for HIV prevention and therapy.Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention Universal antiretroviral regimens: thinking beyond one-pill-once-a-day.The efficacy of an anti-CD4 monoclonal antibody for HIV-1 treatment.Opportunities for therapeutic antibodies directed at G-protein-coupled receptors.Development of tetravalent, bispecific CCR5 antibodies with antiviral activity against CCR5 monoclonal antibody-resistant HIV-1 strains.Parenteral antiretroviral formulations are still urgently needed: a case report and commentary.IBC's 21st Annual Antibody Engineering and 8th Annual Antibody Therapeutics International Conferences and 2010 Annual Meeting of the Antibody Society. December 5-9, 2010, San Diego, CA USA.New Drugs in the Pipeline for the Treatment of HIV: a Review.Ibalizumab Targeting CD4 Receptors, An Emerging Molecule in HIV Therapy.Immunoglobulin G; structure and functional implications of different subclass modifications in initiation and resolution of allergy.HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins Genetic Strategies for HIV Treatment and Prevention

P2860

Q24194805-32FAEF9C-212D-49AC-A082-8E02FBD4094D Q24235689-EB6D1826-A7AA-4964-B05E-757DF18F7528 Q26865457-B69FAFFB-C9B4-4F18-9F91-92AB68FC617D Q30428089-A2E5B3C7-7BF7-46BE-BF3B-3D1DBB76B24C Q33887352-5B2D5BFB-16BE-470A-87D8-18713A069222 Q34150882-8595693B-E2B2-4DB5-AB08-B960776295EF Q34536782-0F495BF1-D9CF-468E-8860-7031A7DC31A3 Q34574397-7C26C10B-C324-45FA-B3B4-7BCC3C0CB8C7 Q34647798-B9DA0E98-7C1A-4B57-9751-DA57DFE086AC Q34939533-1A0B7228-0C0B-45A5-8B55-757623503C7B Q35164438-BC650923-181A-4928-903B-D99E03015B1F Q35693333-C8180BDA-1733-4EC1-9DE0-4B6194F3580B Q36393594-094729BE-D86E-402B-9D9C-63B02E241261 Q36763801-C4FAEE9E-E5D6-4946-8D06-46C15D665710 Q37252004-AA127D2A-2653-4C9C-9876-9671469A548F Q37547093-38F9EB34-5F3C-46D1-A68E-EF5ACCB0A023 Q37779092-C79673E4-06A7-4A42-8D1A-9D8C85D849B0 Q37842335-452D39B8-A5FC-4714-8096-5EC999B163E5 Q37893687-0139BC9D-87A6-4FFB-8751-EDB2B8117D24 Q37998496-17C0B2A9-0F7D-4D17-9A3B-54B120FFB14F Q38196457-72F5AB03-4F03-471A-9E91-9763E6081A9D Q38574172-49E4BACE-A261-48B5-80B8-817FD0B264B6 Q38717198-CD5A529B-0F37-480B-82AE-89F038C1827C Q39161979-D369293E-F7A4-45E9-996F-F02D1CA301B9 Q39215169-B21D3A92-61BF-4563-8C75-ACD941A624FB Q39330860-A65F6DD6-7673-4106-9E15-E85CE9168422 Q39433833-3ABF7499-8BB0-4A2F-8898-F3C9260CAB3B Q39435224-BA4FECC7-2BC7-4CCB-94DF-AE94E0F06C13 Q42212544-A47EF826-BC66-40E0-95FE-2D01434DA3A1 Q42732010-141E921C-16A4-4FA9-A96C-B3651F0FAE26 Q45067800-B5473536-25B0-41B7-A179-9B91D3BFCE83 Q47174470-840DC57C-568C-4343-AB08-DA8500F11020 Q48256010-0CF8C116-857C-482F-958E-10C2106EB160 Q58555325-7BBA4998-F25E-42EF-9A6C-2ECB097BD0F7 Q58604627-1A8CBBFA-0DD6-4B60-9EFA-E02EC149408A

P2860

Anti-HIV-1 activity of weekly or biweekly treatment with subcutaneous PRO 140, a CCR5 monoclonal antibody.

http://www.wikidata.org/entity/Q33798442

description

2010 nî lūn-bûn

@nan

2010 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Anti-HIV-1 activity of weekly ...... 0, a CCR5 monoclonal antibody.

@ast

Anti-HIV-1 activity of weekly ...... 0, a CCR5 monoclonal antibody.

@en

type

label

Anti-HIV-1 activity of weekly ...... 0, a CCR5 monoclonal antibody.

@ast

Anti-HIV-1 activity of weekly ...... 0, a CCR5 monoclonal antibody.

@en

prefLabel

Anti-HIV-1 activity of weekly ...... 0, a CCR5 monoclonal antibody.

@ast

Anti-HIV-1 activity of weekly ...... 0, a CCR5 monoclonal antibody.

@en

P1433

Q33798442-82D35320-CFEF-4FD7-8806-17DD9EDC682A

P1476

Q33798442-5EF361E5-8605-4F83-A798-5FB94010278A

P2093

Q33798442-01317B72-7643-4C6B-BD3C-5262BB06B810

Q33798442-0422E3DB-FB23-4BB4-912F-F142A09F9F38

Q33798442-22818223-8A2E-43DB-A971-F18F19E14B74

Q33798442-74446E75-C0DE-4C0D-8F60-60035686C198

Q33798442-7CBEFA85-832C-4321-81BB-B65582D71448

Q33798442-7EB99E4E-B27B-4EB9-AAB2-71EDCA2751A5

Q33798442-85C21232-1560-4735-B2A1-0133C4B6CC18

Q33798442-B603FF11-A066-4337-AD3B-254FF6D30D06

Q33798442-C7D39BA7-83CB-4739-83C9-8B27E72F34F5

Q33798442-D0C02023-5C4C-4329-987B-B3DD30C52431

P2860

Q33798442-0193E9A9-AA7A-4FC0-9291-D4C112EE2EC7

Q33798442-29EDDD32-970F-4101-A4F7-2E3E2A5120CE

Q33798442-2E533AC2-62A2-4E54-A266-36ECBEA2F718

Q33798442-320BBADC-4192-4605-960C-ADCC72D1FA2B

Q33798442-37C4587E-595D-48BA-BC7E-E89407433E39

Q33798442-3C243BD0-E6E4-40E6-B25F-1E7F8B43EE11

Q33798442-48C63602-A957-4094-B594-5E5B939D8492

Q33798442-4D0740E9-C4A3-4366-B80D-6AEF15F05C4C

Q33798442-5D129DE2-54E8-42DD-97BB-CA454641C86B

Q33798442-612AD090-ECDA-469C-B658-416DC40566F7

P304

Q33798442-D1645651-3969-4806-BB55-F0254D3F5E27

P31

Q33798442-45447244-7CD2-4AEE-8AA7-FD56F0C4D67F

P356

Q33798442-18550F15-72A5-4301-B658-D4F345053DDC

P407

Q33798442-2E630AF8-4FF8-4FA9-AC9E-133195393760

P433

Q33798442-80CDE56F-279A-465B-B84B-0D43CA183D5F

P478

Q33798442-22A7D2E7-086A-46E7-B6BA-AD66D380636E

P577

Q33798442-840F31B1-A9B6-495B-B2BD-D678339181DE

P5875

Q33798442-B38CCBD4-C22B-4327-A804-91943B087438

P698

Q33798442-2AF023D0-E884-4564-BDB9-B5E2C5BA9D69

P921

Q33798442-3B96131E-6BF0-4F6F-8FC5-86617D93618C

P932

Q33798442-27E09291-F993-4D14-8F43-8AB6A2F4DA83

P356

P1433

The Journal of Infectious Diseases

P1476

Anti-HIV-1 activity of weekly ...... 0, a CCR5 monoclonal antibody.

@en

P2093

Andre J Marozsan

http://www.w3.org/2001/XMLSchema#string

Barry S Zingman

http://www.w3.org/2001/XMLSchema#string

Jacob P Lalezari

http://www.w3.org/2001/XMLSchema#string

Jeffrey M Jacobson

http://www.w3.org/2001/XMLSchema#string

Melanie A Thompson

http://www.w3.org/2001/XMLSchema#string

Michael S Saag

http://www.w3.org/2001/XMLSchema#string

Nancy Stambler

http://www.w3.org/2001/XMLSchema#string

Paul D'Ambrosio

http://www.w3.org/2001/XMLSchema#string

Paul J Maddon

http://www.w3.org/2001/XMLSchema#string

Stephen A Morris

http://www.w3.org/2001/XMLSchema#string

P2860

Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies

Potent antiviral synergy between monoclonal antibody and small-molecule CCR5 inhibitors of human immunodeficiency virus type 1

Antiviral activity, pharmacokinetics and safety of vicriviroc, an oral CCR5 antagonist, during 14-day monotherapy in HIV-infected adults

Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140

Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy

Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo.

Biology of CCR5 and its role in HIV infection and treatment.

A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors.

Changes in the risk of death after HIV seroconversion compared with mortality in the general population.

Maraviroc for previously treated patients with R5 HIV-1 infection

P304

1481-1487

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/652190

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

201

http://www.w3.org/2001/XMLSchema#string

P577

2010-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

43078843

http://www.w3.org/2001/XMLSchema#string

P698

20377413

http://www.w3.org/2001/XMLSchema#string

P921

P932

2856743

http://www.w3.org/2001/XMLSchema#string